Chimeric antigen receptor T-cell therapy: Difference between revisions
From IDWiki
(Created page with "== Background == * T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and r...") |
No edit summary |
||
| Line 27: | Line 27: | ||
|Idecabtagene vicleucel |
|Idecabtagene vicleucel |
||
|multiple myeloma |
|multiple myeloma |
||
|B-cell maturation antigen |
|||
|BCMA |
|||
|11.8 month media PFS |
|11.8 month media PFS |
||
|- |
|- |
||
| Line 35: | Line 35: | ||
|18.8 month median OS |
|18.8 month median OS |
||
|} |
|} |
||
== Safety == |
|||
=== Adverse Effects === |
|||
* Prolonged cytopenias and B-cell hypoplasia (causing [[hypogammaglobulinemia]]) |
|||
* Loss of immunity to previous vaccinations |
|||
** Start revaccinating about 6 months after infusion |
|||
=== Cytokine Release Syndrome === |
|||
* Caused by harmful immune system activation |
|||
* Fever is a defining feature, with hypotension and hypoxia in severe disease |
|||
** Often mimics sepsis |
|||
* May also results in [[DIC]], multiorgan failure, and death |
|||
* Treated with corticosteroids and [[tocilizumab]], an IL-6 inhibitor |
|||
* Usually self-limited |
|||
=== Immune Effector Cell-Associated Neurotoxicity Syndrome === |
|||
* ICANS |
|||
* Word-finding difficulty, aphasia, or confusion |
|||
* In severe disease, altered level of consciousness, motor impairment, and cerebral edema |
|||
* Treated with corticosteroids |
|||
* Most cases resolve |
|||
[[Category:Hematology]] |
[[Category:Hematology]] |
||
[[Category:Oncology]] |
[[Category:Oncology]] |
||
Revision as of 11:18, 1 February 2022
Background
- T cells are retrieved from a patient, genetically modified to add a chimeric antigen receptor (CAR) that is specific to the targetted cancer antigen, and reinfused into the patient following a short course of chemotherapy
- Used for relapsed or refractory B-cell acute lymphoblastic leukemia and high-grade B-cell lymphoma
| Product | Indications | Target Antigen | Survival |
|---|---|---|---|
| Tisagenlecleucel | B-ALL and high-grade B-cell lymphoma | CD19 | 76% 1-year OS in B-ALL; 8.3 month median OS in B-cell lymphoma |
| Axicabtagene ciloleucel | high-grade B-cell lymphoma | CD19 | 58% 18-month OS |
| Brexucabtagene autoleucel | mantle cell lymphoma | CD19 | 83% 1-year OS |
| Idecabtagene vicleucel | multiple myeloma | B-cell maturation antigen | 11.8 month media PFS |
| Lisocabtagene maraleucal | high-grade B-cell lymphoma | CD19 | 18.8 month median OS |
Safety
Adverse Effects
- Prolonged cytopenias and B-cell hypoplasia (causing hypogammaglobulinemia)
- Loss of immunity to previous vaccinations
- Start revaccinating about 6 months after infusion
Cytokine Release Syndrome
- Caused by harmful immune system activation
- Fever is a defining feature, with hypotension and hypoxia in severe disease
- Often mimics sepsis
- May also results in DIC, multiorgan failure, and death
- Treated with corticosteroids and tocilizumab, an IL-6 inhibitor
- Usually self-limited
Immune Effector Cell-Associated Neurotoxicity Syndrome
- ICANS
- Word-finding difficulty, aphasia, or confusion
- In severe disease, altered level of consciousness, motor impairment, and cerebral edema
- Treated with corticosteroids
- Most cases resolve
